Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineages.
Zhang, R., Verkoczy, L., Wiehe, K., Munir Alam, S., Nicely, N.I., Santra, S., Bradley, T., Pemble, C.W., Zhang, J., Gao, F., Montefiori, D.C., Bouton-Verville, H., Kelsoe, G., Larimore, K., Greenberg, P.D., Parks, R., Foulger, A., Peel, J.N., Luo, K., Lu, X., Trama, A.M., Vandergrift, N., Tomaras, G.D., Kepler, T.B., Moody, M.A., Liao, H.X., Haynes, B.F.(2016) Sci Transl Med 8: 336ra62-336ra62
- PubMed: 27122615 
- DOI: https://doi.org/10.1126/scitranslmed.aaf0618
- Primary Citation of Related Structures:  
5DD0, 5DD1, 5DD3, 5DD5, 5DD6 - PubMed Abstract: 
Development of an HIV vaccine is a global priority. A major roadblock to a vaccine is an inability to induce protective broadly neutralizing antibodies (bnAbs). HIV gp41 bnAbs have characteristics that predispose them to be controlled by tolerance. We used gp41 2F5 bnAb germline knock-in mice and macaques vaccinated with immunogens reactive with germline precursors to activate neutralizing antibodies ...